Not available

Active Keratosis

Superficial basal cell carcinoma

Adverse Reactions-

Application site disorders     25%

Cardiovascular -   Hypertension    2%

CNS-    Anxiety  1%  Dizziness 1%  Headache   6%

Dermatologic -  Hyperkeratonis  1% Rash   1%  Skin disorder 1%

GI -     Abdominal pain  0.5%   Diarrhea  0.5%     Dyspepsia  1%   GI disorder  0.5%
           Nausea  1%      

Metabolic /nutritional   - Gout  1% 

Musculoskeletal -    Skeletal pain  1% 

Respiratory -  Coughing   1%   Pharyngitis  1%  Rhinitis  2%  Sinusitis  2%

                           Upper respiratory tract infection -  3%

Miscellaneous-   Aggravated allergy -  1%  Back pain 3%   Chest pain 1%  Fatigue  2%
                             Back pain 1%    Chest pain  1%   Fatigue  2%   Fever   1% 
                             Infection   1%     Infection fungal  1%    Infected injury   1%
                             Lymphadenopathy   2%    Pain  1%   Procedural site infection 1% 

Sensitivity  reactions to any of the components

Special precaution-

Inflammatory conditions-  imiquinol has the potential to excerabate inflammatory conditions of the skin

Genital and perianial warts-  local skin reactions at the treatment site are common. A rest period of several days may  be required by the patients discomfort or severity of the local skin reactions. Treatment may resume once the reaction subsides

Nonocclusive dressings-  nonocclusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reaction.

Photosensitivity - Avoid exposure to sunlight or minimise it during use of imiquimod cream
because of concern for hightened sunburn susceptibility 

Pregnancy - No adequate or well controlled studies in pregnant women. Use during pregnancy if potential benefits justifies the potential risk to fetus

Lactation- not known whether topically appied imiquinol is excreted in breast milk.

Children-  Safety and efficacy in patients with external genital/ perianal  warts younger than
12 years of age have not been established

Elderly- no overall differences in safety and efficacy were observed between these and
 younger patients

Indication-
Active Keratosis

Superficial basal cell carcinoma

Dosage-
For external use only- - Imiquimod cream is not opthalmic use.

Apply 2 times per week for 16 weeks to a definite treatment area on the face or scalp ( but not both concurrently ). Treatment should be one  contignous area of approx. 25cm2

1. Follow the doctors instruction regarding the use of this medicine.

2. Do not bandage the treatment area  or otherwise cover or wrap as  to be occlusive

3. Actinic keratosis - it is recommended that the treatment area be washed with mild soap and water  8 hours following imiquimod cream

4. It is common for patients to experience local skin reactions ( mild to severe intensity ) during treatment, and may extend beyond the appilcation site onto the surrounding areas.

5. Skin reactions generally decrease in intensity or resolve after cessation of imiquimod
therapy.

6.Avoid contact with the eyes, lips or nostrils

7. Use of sunscreen is encooraged during tratment.

8. Discard partially used packets and do not reuse.

9. Dosing is twice weekly for the full 16 weeks , unless otherwise directed by the doctor. however, treatment period should not be extended  beyond 16 weeks due to missed doses or rest period

Pregnancy -
No adequate or well controlled studies in pregnant women. Use during pregnancy if
potential benefits justifies the potential risk to fetus

Lactation-
Not known whether topically appied imiquinol is excreted in breast milk.

Children-
Safety and efficacy in patients with external genital/ perianal  warts younger than
12 years of age have not been established

Elderly-
No overall differences in safety and efficacy were observed between these and
 younger patients